TAS2R38

Across TCGA pan-cancer cohorts, TAS2R38 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TAS2R38 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher TAS2R38 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TAS2R38 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, KICH, and UCEC are the cancer types where TAS2R38 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	III,IV	0.175	0.689	<.001	40	view →
KICH	OS	Median	All	0.161	0.881	<.001	24	view →
UCEC	DFS	Median	All	0.969	0.829	.031	10	view →
SCLC	OS	Median	II,III,IV	0.152	0.777	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TAS2R38–LUSC (OS)

Open the LUSC breakdown →